```

[Congressional Bills 115th Congress]
[From the U.S. Government Publishing Office]
[H.R. 5353 Referred in Senate (RFS)]

<DOC>
115th CONGRESS
  2d Session
                                H. R. 5353

_______________________________________________________________________

                   IN THE SENATE OF THE UNITED STATES

                             June 13, 2018

     Received; read twice and referred to the Committee on Health, 
                     Education, Labor, and Pensions

_______________________________________________________________________

                                 AN ACT

 
  To amend the Public Health Service Act to reauthorize and expand a 
 program of surveillance and education, carried out by the Centers for 
 Disease Control and Prevention, regarding infections associated with 
                          injection drug use.

    Be it enacted by the Senate and House of Representatives of the 
United States of America in Congress assembled,

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Eliminating Opioid Related 
Infectious Diseases Act of 2018''.

SEC. 2. REAUTHORIZATION AND EXPANSION OF PROGRAM OF SURVEILLANCE AND 
              EDUCATION REGARDING INFECTIONS ASSOCIATED WITH ILLICIT 
              DRUG USE AND OTHER RISK FACTORS.

    Section 317N of the Public Health Service Act (42 U.S.C. 247b-15) 
is amended to read as follows:

``SEC. 317N. SURVEILLANCE AND EDUCATION REGARDING INFECTIONS ASSOCIATED 
              WITH ILLICIT DRUG USE AND OTHER RISK FACTORS.

    ``(a) In General.--The Secretary may (directly and through grants 
to public and nonprofit private entities) provide for programs for the 
following:
            ``(1) To cooperate with the States and Indian tribes in 
        implementing or maintaining a surveillance system to determine 
        the incidence of infections commonly associated with illicit 
        drug use, including infections commonly associated with 
        injection drug use such as viral hepatitis, human 
        immunodeficiency virus, and infective endocarditis, and to 
        assist the States in determining the prevalence of such 
        infections, which may include the reporting of cases of such 
        infections.
            ``(2) To identify, counsel, and offer testing to 
        individuals who are at risk of infections as a result of 
        injection drug use, receiving blood transfusions prior to July 
        1992, or other risk factors.
            ``(3) To provide appropriate referrals for counseling, 
        testing, and medical treatment of individuals identified under 
        paragraph (2) and to ensure, to the extent practicable, the 
        provision of appropriate follow-up services.
            ``(4) To develop and disseminate public information and 
        education programs for the detection and control of infections 
        described in paragraph (1), with priority given to high-risk 
        populations as determined by the Secretary.
            ``(5) To improve the education, training, and skills of 
        health professionals in the detection and control of infections 
        and the coordination of treatment of addiction and infectious 
        diseases described in paragraph (1), with priority given to 
        substance use disorder treatment providers, pediatricians and 
        other primary care providers, obstetrician-gynecologists, 
        infectious diseases clinicians, and HIV clinicians.
    ``(b) Laboratory Procedures.--The Secretary may (directly or 
through grants to public and nonprofit private entities) carry out 
programs to provide for improvements in the quality of clinical-
laboratory procedures regarding infections described in subsection 
(a)(1).
    ``(c) Definitions.--In this section:
            ``(1) The term `Indian tribe' has the meaning given that 
        term in section 4 of the Indian Self-Determination and 
        Education Assistance Act.
            ``(2) The term `injection drug use' means--
                    ``(A) intravenous administration of a substance in 
                schedule I under section 202 of the Controlled 
                Substances Act;
                    ``(B) intravenous administration of a substance in 
                schedule II, III, IV, or V under section 202 of the 
                Controlled Substances Act that has not been approved 
                for intravenous use under--
                            ``(i) section 505 of the Federal Food, Drug 
                        and Cosmetic Act; or
                            ``(ii) section 351 of the Public Health 
                        Service Act; or
                    ``(C) intravenous administration of a substance in 
                schedule II, III, IV, or V under section 202 of the 
                Controlled Substances Act that has not been prescribed 
                to the person using the substance.
    ``(d) Authorization of Appropriations.--For the purpose of carrying 
out this section, there are authorized to be appropriated $40,000,000 
for each of the fiscal years 2019 through 2023.''.

            Passed the House of Representatives June 12, 2018.

            Attest:

                                                 KAREN L. HAAS,

                                                                 Clerk.
```